Bio-Rad Laboratories, Inc. BIOB
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About BIOB
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Bio-Rad Laboratories, Inc. is a U.S.-based life science research and clinical diagnostics company that develops, manufactures, and distributes analytical instruments, reagents, software, and consumables used in laboratories worldwide. The company operates primarily in the biotechnology, pharmaceutical, healthcare, academic research, and clinical diagnostics industries. Its operations are organized around two principal business segments: Life Science and Clinical Diagnostics. Revenue is generated through sales of instruments, recurring consumables, quality-control products, and diagnostic testing solutions used in molecular biology, cell biology, protein analysis, blood typing, infectious disease testing, and laboratory quality assurance.
Founded in 1952 by David and Alice Schwartz in California, Bio-Rad initially focused on specialty chemicals for research laboratories before expanding into analytical instrumentation and diagnostics through internal development and acquisitions. The company has established a long-standing position in areas such as droplet digital PCR (ddPCR), electrophoresis, chromatography, and quality-control systems for clinical laboratories. Its strategic advantages include a broad installed base of laboratory instruments, recurring consumables revenue, extensive intellectual property in molecular analysis technologies, and diversified exposure across research and healthcare end markets.
Business Operations
Bio-Rad conducts operations through its Life Science and Clinical Diagnostics segments. The Life Science segment supplies instruments, software, reagents, and consumables used in genomics, proteomics, cell biology, food safety, and biopharmaceutical production workflows. Major product categories include PCR systems, ddPCR platforms, imaging systems, chromatography products, and electrophoresis solutions. The Clinical Diagnostics segment provides products for blood typing, autoimmune and infectious disease testing, diabetes monitoring, and quality-control products used by hospitals and reference laboratories. A substantial portion of revenue is generated from recurring consumables and reagent sales tied to the installed instrument base.
The company maintains manufacturing, distribution, and commercial operations across North America, Europe, Asia-Pacific, and Latin America. Bio-Rad controls a large portfolio of proprietary technologies and patents related to molecular diagnostics and laboratory workflows. It also holds a significant equity stake in Sartorius AG, originally established through a strategic investment that has become a major financial asset on its balance sheet. Subsidiaries and regional operating entities support direct sales and distribution activities in major scientific and healthcare markets globally.
Strategic Position & Investments
Bio-Rad’s strategic direction has focused on expanding high-margin recurring revenue streams, advancing molecular diagnostics technologies, and strengthening its position in life science research tools. The company has invested heavily in digital PCR technology, biopharmaceutical process analytics, and clinical quality-control systems. Its ddPCR platform has been adopted in applications including oncology research, infectious disease monitoring, gene expression analysis, and cell and gene therapy development. Bio-Rad has also pursued acquisitions and product development initiatives aimed at enhancing automation, multiplex testing capabilities, and software-enabled laboratory workflows.
The company’s investment in Sartorius AG remains one of its most notable strategic holdings and has materially influenced Bio-Rad’s financial position in recent years. Bio-Rad has additionally expanded capabilities through acquisitions including DropWorks, Inc., which strengthened its digital PCR and droplet-generation technologies. The company continues to participate in emerging sectors tied to precision medicine, biologics manufacturing, advanced genomics, and laboratory automation, while emphasizing operational efficiency and long-term research and diagnostics market growth.
Geographic Footprint
Bio-Rad is headquartered in Hercules, California, and operates globally across the Americas, Europe, Asia-Pacific, and other international markets. The company maintains manufacturing facilities, research centers, distribution infrastructure, and commercial offices in multiple countries, including the United States, France, Germany, Switzerland, Singapore, and China. International markets account for a substantial portion of consolidated revenue, with Europe representing a particularly important region for both life science and diagnostics operations.
The company’s products are sold in more than 100 countries through direct sales organizations and distributor networks. Bio-Rad has established a strong presence in developed healthcare and research markets while also expanding in emerging economies where investments in biotechnology and clinical laboratory infrastructure continue to grow. Its international operational footprint supports pharmaceutical customers, academic institutions, hospitals, diagnostic laboratories, and industrial research organizations worldwide.
Leadership & Governance
Bio-Rad remains influenced by its founding family through long-term governance participation and strategic oversight. The company historically emphasized scientific innovation, decentralized operational expertise, and sustained investment in research-oriented technologies. Leadership has focused on balancing organic growth, operational discipline, and strategic capital allocation while maintaining a diversified exposure to both research and clinical diagnostics markets.
Key executives and leadership figures include:
- Norman Schwartz – Chairman of the Board
- Jennifer M. Chao – President and Chief Executive Officer
- Ilia G. Yuffa – Executive Vice President and President, Life Science Group
- John Hertia – Executive Vice President and President, Clinical Diagnostics Group
- Christine A. Tsingos – Executive Vice President, Chief Financial Officer
- Michael Crowley – Executive Vice President, Global Commercial Operations
- Andrew Last – Executive Vice President, General Counsel and Corporate Secretary
Leadership strategy, as reflected in public filings and investor communications including SEC filings and annual reports, emphasizes innovation in molecular biology and diagnostics, disciplined portfolio management, recurring revenue growth, and continued expansion of global laboratory solutions capabilities.